Targeting phosphatidylinositol 3-kinase-Akt through hepatocyte growth factor for cardioprotection

Journal of Cardiovascular Medicine

Volumn 14, Issue 4, 2013, Pages 249-253

  Madonna, Rosalinda ^a   Bolli, Roberto ^b   Rokosh, Gregg ^b   De Caterina, Raffaele ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b University of Louisville School of Medicine   (United States)

Author keywords

Akt; Apoptosis; Cardioprotection; Hepatocyte growth factor; MET receptor; Phosphatidylinositol 3 kinase; PI3K

Indexed keywords

APOPTOSIS INDUCING FACTOR; BINDING PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GROWTH FACTOR RECEPTOR BOUND PROTEIN ASSOCIATED BINDER 1; INHIBITOR OF APOPTOSIS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROCASPASE 9; PROTECTIVE AGENT; PROTEIN BCL 2; PROTEIN BCL 2A1; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; SCATTER FACTOR; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG;

ADIPOSE DERIVED STEM CELL; ANGIOGENESIS; APOPTOSIS; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CELL REGENERATION; CELL SURVIVAL; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE TRANSFER; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; MITOGENESIS; NONHUMAN; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

APOPTOSIS; CARDIOTONIC AGENTS; HEPATOCYTE GROWTH FACTOR; HUMANS; MYOCARDIAL REPERFUSION INJURY; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84875225885     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283542017     Document Type: Review

References (45)

1. Schwartz Longacre L, Kloner RA, Arai AE, et al. New horizons in cardioprotection: Recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation 2010; 124:1172-1179
2. Bolli R. Preconditioning: A paradigm shift in the biology of myocardial ischemia. Am J Physiol Heart Circ Physiol 2007; 292:H19-27
3. Lefer DJ, Bolli R. Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): A paradigm shift in studies of infarct size limitation. J Cardiovasc Pharmacol Ther 2011; 16:332-339
4. Nakamura T, Mizuno S, Matsumoto K, et al. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000; 106:1511-1519
5. Ono K, Matsumori A, Shioi T, et al. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997; 95:2552-2558
6. Ueda H, Nakamura T, Matsumoto K, et al. A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats. Cardiovasc Res 2001; 51:41-50
7. Suzuki YJ. Growth factor signaling for cardioprotection against oxidative stress-induced apoptosis. Antioxid Redox Signal 2003; 5:741-749
8. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984; 122:1450-1459
9. Balkovetz DF, Lipschutz JH. Hepatocyte growth factor and the kidney: It is not just for the liver. Int Rev Cytol 1999; 186:225-260
10. Matsumori A, Furukawa Y, Hashimoto T, et al. Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction. Biochem Biophys Res Commun 1996; 221:391-395
11. Rosario M, Birchmeier W. How to make tubes: Signaling by the Met receptor tyrosine kinase. Trends Cell Biol 2003; 13:328-335
12. Sussman MA, Volkers M, Fischer K, et al. Myocardial AKT: The omnipresent nexus. Physiol Rev 91:1023-1070
13. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT: A major therapeutic target. Biochim Biophys Acta 2004; 1697:3-16
14. Ronnebaum SM, Patterson C. The FoxO family in cardiac function and dysfunction. Annu Rev Physiol 2010; 72:81-94
15. Dijkers PF, Medema RH, Lammers JW, et al. Expression of the proapoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000; 10:1201-1204
16. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-Associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14:5579-5588
17. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10:26-35
18. Chipuk JE, Moldoveanu T, Llambi F, et al. The BCL-2 family reunion. Mol Cell 2010; 37:299-310
19. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26:1324-1337
20. Wagner M, Siddiqui MA. Signaling networks regulating cardiac myocyte survival and death. Curr Opin Investig Drugs 2009; 10:928-937
21. Bhuiyan MS, Fukunaga K. Inhibition of HtrA2/Omi ameliorates heart dysfunction following ischemia/reperfusion injury in rat heart in vivo. Eur J Pharmacol 2007; 557:168-177
22. Kossmehl P, Kurth E, Faramarzi S, et al. Mechanisms of apoptosis after ischemia and reperfusion: Role of the renin-Angiotensin system. Apoptosis 2006; 11:347-358
23. Gomez L, Chavanis N, Argaud L, et al. Fas-independent mitochondrial damage triggers cardiomyocyte death after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2005; 289:H2153-2158
24. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251:802-804
25. Xiao GH, Jeffers M, Bellacosa A, et al. Antiapoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-Activated protein kinase pathways. Proc Natl Acad Sci U S A 2001; 98:247-252
26. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4:915-925
27. Bhuiyan MS, Shioda N, Fukunaga K. Targeting protein kinase B/Akt signaling with vanadium compounds for cardioprotection. Expert Opin Ther Targets 2008; 12:1217-1227
28. Madonna R, Delli Pizzi S, Di Donato L, et al. Non-invasive in vivo detection of peripheral limb ischemia improvement in the rat after adipose tissue-derived stromal cell transplantation. Circ J 2012. [Epub ahead of print
29. Madonna R, De Caterina R. Stem cells and growth factor delivery systems for cardiovascular disease. J Biotechnol 2011; 154:291-297
30. Madonna R, Rokosh G, De Caterina R, Bolli R. Hepatocyte growth factor/ Met gene transfer in cardiac stem cells: Potential for cardiac repair. Basic Res Cardiol 2010; 105:443-452
31. Smyth LA, Brady HJ. cMet and Fas receptor interaction inhibits deathinducing signaling complex formation in endothelial cells. Hypertension 2005; 46:100-106
32. Wang X, DeFrances MC, Dai Y, et al. A mechanism of cell survival: Sequestration of Fas by the HGF receptor Met. Mol Cell 2002; 9:411-421
33. Huh CG, Factor VM, Sanchez A, et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A 2004; 101:4477-4482
34. Kosai K, Matsumoto K, Nagata S, et al. Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun 1998; 244:683-690
35. Suzuki A, Hayashida M, Kawano H, et al. Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. Hepatology 2000; 32:796-802
36. Schulze-Bergkamen H, Brenner D, Krueger A, et al. Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt. Hepatology 2004; 39:645-654
37. Khai NC, Takahashi T, Ushikoshi H, et al. In vivo hepatic HB-EGF gene transduction inhibits Fas-induced liver injury and induces liver regeneration in mice: A comparative study to HGF. J Hepatol 2006; 44:1046-1054
38. Conner EA, Teramoto T, Wirth PJ, et al. HGF-mediated apoptosis via p53/ bax-independent pathway activating JNK1. Carcinogenesis 1999; 20:583-590
39. Matteucci E, Modora S, Simone M, Desiderio MA. Hepatocyte growth factor induces apoptosis through the extrinsic pathway in hepatoma cells: Favouring role of hypoxia-inducible factor-1 deficiency. Oncogene 2003; 22:4062-4073
40. Rasola A, Anguissola S, Ferrero N, et al. Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res 2004; 64:1744-1750
41. Gonzalez-Pertusa JA, Dube J, Valle SR, et al. Novel proapoptotic effect of hepatocyte growth factor: Synergy with palmitate to cause pancreatic {beta}-cell apoptosis. Endocrinology 2010; 151:1487-1498
42. Sato T, Tani Y, Murao S, et al. Focal enhancement of expression of c-Met/ hepatocyte growth factor receptor in the myocardium in human myocardial infarction. Cardiovasc Pathol 2001; 10:235-240
43. Sato T, Fujieda H, Murao S, et al. Sequential changes of hepatocyte growth factor in the serum and enhanced c-Met expression in the myocardium in acute myocardial infarction. Jpn Circ J 1999; 63:906-908
44. Sato T, Yoshinouchi T, Sakamoto T, et al. Hepatocyte growth factor (HGF): A new biochemical marker for acute myocardial infarction. Heart Vessels 1997; 12:241-246
45. Yasuda S, Goto Y, Baba T, et al. Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J Am Coll Cardiol 2000; 36:115-121